Revolution Medicines, Inc. (NASDAQ:RVMDW – Get Free Report) saw a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 703 shares, a decrease of 64.8% from the August 31st total of 2,000 shares. Based on an average daily volume of 25,844 shares, the short-interest ratio is currently 0.0 days.
Revolution Medicines Stock Performance
Revolution Medicines stock traded up $0.65 on Friday, hitting $11.40. 116,314 shares of the stock traded hands, compared to its average volume of 105,124. The business’s fifty day simple moving average is $10.85 and its 200 day simple moving average is $7.23. Revolution Medicines has a 1 year low of $0.23 and a 1 year high of $13.44.
About Revolution Medicines
Revolution Medicines, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company specializes in medicines designed to inhibit mutated RAS proteins, including KRAS, which are important drivers of many solid tumors and have historically been difficult to target with drugs.
Its research and development pipeline includes RAS(ON) inhibitors intended to block active forms of RAS signaling. Key investigational programs have included pan-RAS inhibitors and mutation-selective candidates directed at alterations such as KRAS G12C and KRAS G12D.
Further Reading
- Five stocks we like better than Revolution Medicines
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
